Logo image
Back
Abstract 3175: Detection of hypermethylated vimentin gene in urine of colorectal cancer patients
Journal article   Open access   Peer reviewed

Abstract 3175: Detection of hypermethylated vimentin gene in urine of colorectal cancer patients

Benjamin P. Song, Surbhi Jain, Selena Y. Lin, Timothy M. Block, Dean E. Brenner and Ying-Hsiu Su
Cancer research (Chicago, Ill.), v 71(8_Supplement), pp 3175-3175
15 Apr 2011
DOI: https://doi.org/10.1158/1538-7445.AM2011-3175
url
https://doi.org/10.1158/1538-7445.AM2011-3175View
Published, Version of Record (VoR)Open Access (License Unspecified),  Open

Abstract

Abstract Although the success of cancer treatment often depends on the early detection of cancer, colorectal cancer (CRC) screening is hindered by low compliance rates (40%) of inconvenient, invasive screening tests. Previous studies have demonstrated that urine contains circulation-derived low-molecular-weight (LMW) DNA (<300 bp) and suggested that LMW urine DNA could be used to detect CRC associated genetic alterations. Aberrant hypermethylation of the vimentin gene (mVIM) has been shown to be a potential stool DNA marker for CRC screening. It was of interest to see whether mVIM could be detected in urine of patients with CRC. In this study, we developed a quantitative MethyLight assay targeting a 39 bp DNA template for mVIM. A locked nucleic acid was incorporated at the CpG sites of the reverse primer of the assay to increase the assay sensitivity and specificity for methylated templates. A blinded concordance study between urine and matched CRC tissue was performed. Twenty matched sets of urine and CRC tissue were collected and subjected to DNA isolation. Total urine DNA was further fractionated into both LMW DNA (< 1 kb) and high-molecular-weight (HMW) DNA (>1 kb) fractions. The MethyLight assay was used to quantify the amount of mVIM in each DNA sample. mVIM was detected in 75% (15/20) of the LMW urine DNA fraction, 0% (0/20) of the HMW urine DNA fraction and 85% (17/20) of the CRC tissue DNA. There was a 60% concordance in detecting mVIM between the CRC tissues and their corresponding urine samples. As negative controls, twenty LMW urine DNA fractions from subjects with no known neoplasia were also tested for mVIM and only 10% (2/20) of control samples contained detectable mVIM. mVIM may be a useful part of a urine based genetic biomarker panel for the early detection of CRC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3175. doi:10.1158/1538-7445.AM2011-3175

Metrics

6 Record Views

Details

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Oncology
Logo image